Prana is pleased to announce that further analysis of the results of its REACH2HD trial will be featured at the 20th Annual International Movement Disorder Society Congress.

Prana has today announced that is has received a A$6.5 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.

Prana presents unique drug platform at World Orphan Drug Congress

Prana regains compliance with NASDAQ continued listing requirements and continues to work towards FDA submission